It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story even if these companies are loss-making. Sometimes these stories can cloud the minds of investors, leading them to invest with their emotions rather than on the merit of good company fundamentals. While a well funded company may sustain losses for years, it will need to generate a profit eventually, or else investors will move on and the company will wither away.
So if this idea of high risk and high reward doesn't suit, you might be more interested in profitable, growing companies, like BLS Pharmaceuticals (ASX:BLS). While profit isn't the sole metric that should be considered when investing, it's worth recognising businesses that can consistently produce it.
How Fast Is BLS Pharmaceuticals Growing Its Earnings Per Share?
BLS Pharmaceuticals has undergone a massive growth in earnings per share over the last three years. So much so that this three year growth rate wouldn't be a fair assessment of the company's future. Thus, it makes sense to focus on more recent growth rates, instead. In impressive fashion, BLS Pharmaceuticals' EPS grew from AU$0.024 to AU$0.067, over the previous 12 months. It's not often a company can achieve year-on-year growth of 184%. Shareholders will be hopeful that this is a sign of the company reaching an inflection point.
Top-line growth is a great indicator that growth is sustainable, and combined with a high earnings before interest and taxation (EBIT) margin, it's a great way for a company to maintain a competitive advantage in the market. Not all of BLS Pharmaceuticals' revenue last year was revenue from operations, so keep in mind the revenue and margin numbers used in this article might not be the best representation of the underlying business. While we note BLS Pharmaceuticals achieved similar EBIT margins to last year, revenue grew by a solid 152% to AU$74m. That's encouraging news for the company!
The chart below shows how the company's bottom and top lines have progressed over time. For finer detail, click on the image.
Check out our latest analysis for BLS Pharmaceuticals
Since BLS Pharmaceuticals is no giant, with a market capitalisation of AU$244m, you should definitely check its cash and debt before getting too excited about its prospects.
Are BLS Pharmaceuticals Insiders Aligned With All Shareholders?
It's said that there's no smoke without fire. For investors, insider buying is often the smoke that indicates which stocks could set the market alight. Because often, the purchase of stock is a sign that the buyer views it as undervalued. However, small purchases are not always indicative of conviction, and insiders don't always get it right.
With strong conviction, BLS Pharmaceuticals insiders have stood united by refusing to sell shares over the last year. But the real excitement comes from the AU$90k that CEO, MD & Executive Director Samuel Watson spent buying shares (at an average price of about AU$0.50). Purchases like this clue us in to the to the faith management has in the business' future.
On top of the insider buying, we can also see that BLS Pharmaceuticals insiders own a large chunk of the company. In fact, they own 52% of the company, so they will share in the same delights and challenges experienced by the ordinary shareholders. This should be seen as a good thing, as it means insiders have a personal interest in delivering the best outcomes for shareholders. In terms of absolute value, insiders have AU$126m invested in the business, at the current share price. So there's plenty there to keep them focused!
Should You Add BLS Pharmaceuticals To Your Watchlist?
BLS Pharmaceuticals' earnings per share have been soaring, with growth rates sky high. To sweeten the deal, insiders have significant skin in the game with one even acquiring more. This quick rundown suggests that the business may be of good quality, and also at an inflection point, so maybe BLS Pharmaceuticals deserves timely attention. What about risks? Every company has them, and we've spotted 1 warning sign for BLS Pharmaceuticals you should know about.
Keen growth investors love to see insider activity. Thankfully, BLS Pharmaceuticals isn't the only one. You can see a a curated list of Australian companies which have exhibited consistent growth accompanied by high insider ownership.
Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.